Search
Ezobresib
go.drugbank.com/drugs/DB15435InvestigationalBMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
Glucoraphanin
go.drugbank.com/drugs/DB15436InvestigationalGlucoraphanin is under investigation in clinical trial NCT01879878 (Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]).
Pabinafusp alfa
go.drugbank.com/drugs/DB15633InvestigationalPabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With Mucopolysaccharidosis II).
Navacaprant
go.drugbank.com/drugs/DB16068InvestigationalBTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).
Artemisone
go.drugbank.com/drugs/DB16097InvestigationalArtemisone is under investigation in clinical trial NCT00936767 (Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia).
Denagliptin
go.drugbank.com/drugs/DB16134InvestigationalDenagliptin is under investigation in clinical trial NCT00387972 (Study of Denagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM)).
10-hydroxycamptothecin
go.drugbank.com/drugs/DB12385Experimental10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).
Levonadifloxacin
go.drugbank.com/drugs/DB16219InvestigationalLevonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections
Benapenem
go.drugbank.com/drugs/DB18883InvestigationalBenapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis
Cedirogant
go.drugbank.com/drugs/DB18951InvestigationalCedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis